Exclusive Summary

• Originator patents have long expired, offering zero IP barriers for immediate registration and distribution launch by overseas partners.
• Driven by over 20 million new global cancer cases annually, there is immense demand in emerging markets for cost-effective oncology adjuvant therapies and immunomodulators.
• Generic competition is highly regionalized (mostly in China and Japan), offering overseas distributors excellent opportunities to capture 'first-to-market' generic status in untapped niche markets.
• Leveraging China's fully integrated API-to-FDF supply chain, the product yields unparalleled cost advantages, securing high profit margins and competitive tender pricing for distributors.